Peter Dudek (@dud3k) profile picture

Scientist turned investor. Managing Partner at MRL Ventures @Merck. Opinions are my own etc

Cambridge, MA
Joined May 2011
Photo by Peter Dudek (@dud3k)Photo by Peter Dudek (@dud3k)Photo by Peter Dudek (@dud3k)Photo by Peter Dudek (@dud3k)Photo by Peter Dudek (@dud3k)Photo by Peter Dudek (@dud3k)Photo by Peter Dudek (@dud3k)Photo by Peter Dudek (@dud3k)Photo by Peter Dudek (@dud3k)Photo by Peter Dudek (@dud3k)
Very excited to be part of the story including at the company’s nucleation. For us, the Ambagon story began in 2019 with Michelle Arkin’s talk at Science2Startup here in Cambridge! Bring it back @LifeSciVC! 😉
Congratz to the exceptional Ambagon team + founders! $85M led by @NextechInvest brings total VC to >$100M after $18M seed by AbbVie, Merck, INKEF, DROIA and RA Capital. Also excited to welcome aboard Surveyor.
4
I’m coming out of hiding to say that we’re thrilled to be backing Nan Ji and PAQ Therapeutics for its Series A announced today. The TPD space continues to evolve and we’re very excited to continue to invest in this exciting modality. fiercebiotech.com/biotech/pa…
3
Peter Dudek retweeted
Relying on a bubbly immune cell that eats pathogens and often gathers around solid tumors, the team at Carisma Therapeutics hopes CAR-M can bring the benefits of cell therapy into places where CAR-T has consistently failed. endpts.com/car-m-era-begins-…
Peter Dudek retweeted
Here is a head-to-head comparison of the he Pfizer/BioNTech and Moderna vaccines buff.ly/3ocII2r
3
29
4
43
The approval of risdiplam, an RNA-targeted small-molecule splicing modulator, for patients with SMA is a landmark - a powerful example of how straight the line can sometimes be from scientific insight to patient benefit.
3
14
2
115
On the heels of its first IND, Carisma’s science makes the cover of the latest issue of @NatureBiotech nature.com/nbt/volumes/38/is…
2
Huge congrats to the team at Carisma for its first IND! Engineered macrophages are headed to the clinic. carismatx.com/carisma-therap…
2
Excited to partner with @sanofi to power up our IRAK4 program in immune-inflammatory diseases. Fulfilling our mission to ensure broadest patient impact of our degrader drugs while retaining value and growing our clinical and commercial capabilities. https://teapawt.net/t.co/RASXHBEWLS
15
13
5
101
Peter Dudek retweeted
The trillion dollar question. Why are COVID cases increasing while deaths are decreasing? The answer is simple. It's called Simpson's paradox and it's the result of incorrectly pooling data and arriving at a false conclusion. A thread 1/9 #COVID19 #ThursdayThoughts
1,127
20,476
4,342
50,218
This figure from a recent Cell Metabolism review sparked an internal debate about science and communication. What's your favorite facepalm-inducing scientific diagram? Rules: must have been made (or reviewed) by a real scientist #sciencetwitter
1
1
Peter Dudek retweeted
New study by @IdoAmitLab on scRNA-seq in mild (n=3) vs severe (n=6) COVID-19 patient, w/ computational disentangling of cells directly infected by SARS-CoV-2 vs those indirectly impacted. sciencedirect.com/science/ar…
4
12
1
43
Peter Dudek retweeted
Urgent message to the #biotweet universe:my colleague’s dad is in ICU in Green Bay, WI and near the end of treatment options for #covid19. Asking for plasma donors who have previously recovered.Still confirming his blood type, O negative donors for now. Please DM if have leads!
2
24
21
Peter Dudek retweeted
Encouraging news for #COVID19 vaccines: preprint shows inactivated #SARSCoV2 virus injected into rodents & monkeys induces neutralizing antibodies against 10 representative SARS-CoV-2 strains & provides protection from live virus in monkeys, w/o AME/ADE. biorxiv.org/content/10.1101/…
16
253
35
708